Pfizer Inc and Bristol-Myers Squibb Company have announced an update on their Phase 1B, open-label clinical study evaluating the combination of elranatamab and iberdomide for treating relapsed or refractory multiple myeloma. The study assesses the safety and tolerability of the drug combination, with elranatamab administered via subcutaneous injection and iberdomide taken orally in a 21-day cycle within a 28-day cycle. The trial began on February 20, 2024, with an initial submission on January 10, 2024, and the latest update was submitted on August 12, 2025. The study is currently recruiting and could influence stock performance and the competitive dynamics in the oncology sector.

Worldwide Market Reports has released an analysis of the Blockbuster Oncology Brands Market, highlighting the industry's shift toward next-generation cancer therapeutics with significant revenue potential. The report identifies key drivers such as rising global cancer incidence, breakthrough immuno-oncology treatments, and accelerated regulatory approvals from the FDA and EMA. Market growth is fueled by precision oncology, combination therapies (especially immunotherapy with chemotherapy), and biomarker-driven patient targeting. Major pharmaceutical companies including Roche, Bristol Myers Squibb, Merck, Novartis, AstraZeneca, Pfizer, Johnson & Johnson (Janssen), Gilead, Takeda, and Eli Lilly are leading the market. North America holds the largest market share, while Asia-Pacific is the fastest-growing region. Key trends include expansion into rare cancers, tumor-agnostic therapies, AI in clinical trial design, and improved patient adherence through digital tools.

The global immunology market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033. Growth is driven by rising prevalence of chronic diseases, increased awareness of immune-related conditions, and greater investment in research and development. However, stringent regulatory requirements pose challenges. Key factors include advancements in biotechnology and molecular biology. Major partnerships include Gilead Sciences' exclusive license with Xilio Therapeutics for tumor-activated IL-12 therapy (XTX301), and an expanded collaboration with Arcus Biosciences to include inflammatory disease therapies. The biopharmaceuticals segment and autoimmune disease application dominate market share. Hospitals and clinics are the leading end-user segment. North America and Europe have mature markets, while Asia-Pacific and LAMEA are experiencing rapid growth due to rising healthcare spending and awareness.

The Saudi Arabia Diabetes Drug Market is projected to grow from US$773.6 million in 2024 to US$1.33 billion by 2033 at a 6.22% CAGR, driven by rising diabetes prevalence due to sedentary lifestyles, obesity, and government initiatives under Vision 2030. The market is shifting toward advanced therapeutics such as SGLT2 inhibitors, GLP-1 receptor agonists, and biosimilar insulins, which offer improved glycemic control and cardiovascular benefits. Key players including Novo Nordisk, Sanofi, AstraZeneca, Biocon, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Novartis are active in the market. Government investments in healthcare infrastructure, public awareness campaigns, and policies like a 50% tax on sugary beverages and 100% tax on energy drinks are supporting market expansion. However, challenges remain, including high costs of newer drugs, limited access in rural areas, and low awareness of diabetes symptoms and treatment options. A major development in October 2024 was a deal between NUPCO, Sudair Pharmaceutical, Sanofi, and Novo Nordisk to localize insulin production.

Pfizer's non-COVID drug sales are showing strong growth in the first half of 2025, driven by key products such as Vyndaqel, Padcev, Eliquis, and newly acquired Seagen products like Adcetris, Tukysa, and Tivdak. The company reported $4.7 billion in revenue from these products, representing a 15% increase over the previous year. Pfizer gained approval for a gene therapy for hemophilia, Hympavzi, in 2024 and acquired Seagen in December 2023, which has significantly strengthened its oncology portfolio. Despite challenges including Medicare Part D headwinds, upcoming exclusivity losses from 2026 to 2030, and macroeconomic volatility, Pfizer expects sustained revenue growth at a 6% CAGR from 2025 to 2030, with Seagen contributing over $10 billion in risk-adjusted revenues by 2030. The company's stock is trading at a forward P/E of 7.95, below its 5-year mean of 10.79 and industry average of 13.73, making it relatively attractive compared to peers like AstraZeneca, Merck, and Bristol-Myers. AstraZeneca, Merck, and Bristol-Myers also reported strong oncology performance in the first half of 2025, with Keytruda driving 50% of Merck’s sales and Opdivo accounting for 20% of Bristol-Myers’ total revenues.